Sugi Predict

Sugi Predict / Compounds / SCHEMBL181107

SCHEMBL181107

SCHEMBL181107

O=c1c(O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HB P07237 6/20 0.70
▸ GAA P10253 5/20 0.70
▸ KDM4E B2RXH2 5/20 0.70
▸ POLB P06746 4/20 0.70
▸ MAPT P10636 4/20 0.70
▸ L3MBTL1 Q9Y468 4/20 0.70
▸ SLCO2B1 O94956 4/20 0.70
▸ ALDH1A1 P00352 3/20 0.70
▸ MPI P34949 2/20 0.70
▸ NAMPT P43490 1/20 0.70
▸ RECQL P46063 1/20 0.70
▸ TDP1 Q9NUW8 1/20 0.70
▸ EPHX2 P34913 4/20 0.68
▸ PTGS1 P23219 1/20 0.68
▸ PTGS2 P35354 1/20 0.68
▸ AKR1B1 P15121 4/20 0.57
▸ MAOA P21397 3/20 0.57
▸ XDH P47989 3/20 0.57
▸ PIM2 Q9P1W9 2/20 0.57
▸ CA12 O43570 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14167721 1.00 P4HB (0.70) P4HBGAAKDM4EPOLBMAPT
SCHEMBL9983362 1.00 P4HB (0.70) P4HBGAAKDM4EPOLBMAPT
SCHEMBL15633866 1.00 P4HB (0.70) P4HBGAAKDM4EPOLBMAPT
Reynoutrin SCHEMBL4226891 0.90 KDM4E (0.71) P4HBGAAKDM4EPOLBMAPT
Reynoutrin SCHEMBL38138 0.90 KDM4E (0.71) P4HBGAAKDM4EPOLBMAPT
Reynoutrin SCHEMBL6759025 0.90 KDM4E (0.71) P4HBGAAKDM4EPOLBMAPT
Guajaverin SCHEMBL3635416 0.90 KDM4E (0.71) P4HBGAAKDM4EPOLBMAPT
Reynoutrin SCHEMBL5590747 0.90 KDM4E (0.71) P4HBGAAKDM4EPOLBMAPT
Reynoutrin SCHEMBL20298285 0.90 KDM4E (0.71) P4HBGAAKDM4EPOLBMAPT
Reynoutrin SCHEMBL14350762 0.90 KDM4E (0.71) P4HBGAAKDM4EPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200297692-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE MERCK SHARP & DOHME CORP. (US) 2020-09-24 — — US disclosed
US-10709684-B2 SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease MERCK SHARP & DOHME CORP. (US) 2020-07-14 — — US disclosed
US-20200054598-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE MERCK SHARP & DOHME CORP. (US) 2020-02-20 — — US disclosed
US-10500186-B2 SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease MERCK SHARP & DOHME CORP. (US) 2019-12-10 — — US disclosed
US-20190142793-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE MERCK SHARP & DOHME CORP. (US) 2019-05-16 — — US disclosed
US-10285973-B2 SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease MERCK SHARP & DOHME CORP. (US) 2019-05-14 — — US disclosed
US-20170304262-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE MERCK SHARP & DOHME LLC 2017-10-26 — — US disclosed
US-9439901-B2 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives PFIZER INC. (US) 2016-09-13 — — US disclosed
US-9439902-B2 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives PFIZER INC. (US) 2016-09-13 — — US disclosed
US-9308204-B2 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives PFIZER INC. (US) 2016-04-12 — — US disclosed
WO-2010023594-A1 DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES PFIZER INC. (US) 2010-03-04 — — WO disclosed
US-20100056618-A1 DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES PFIZER INC 2010-03-04 — — US disclosed
US-20070292539-A1 Anti-inflammatory cranberry flavonol extract preparations VORSA NICHOLI 2007-12-20 — — US disclosed
US-20070292539-A1 Anti-inflammatory cranberry flavonol extract preparations VORSA NICHOLI 2007-12-20 — — US disclosed
US-20070292539-A1 Anti-inflammatory cranberry flavonol extract preparations VORSA NICHOLI 2007-12-20 — — US disclosed
US-7270837-B2 free of anthocyanins and proanthocyanidins; treatment of inflammatory disorders, particularly irritation of the urinary tract due to both bacterial and non-bacterial causes RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-09-18 — — US disclosed
US-7270837-B2 free of anthocyanins and proanthocyanidins; treatment of inflammatory disorders, particularly irritation of the urinary tract due to both bacterial and non-bacterial causes RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-09-18 — — US disclosed
US-7270837-B2 free of anthocyanins and proanthocyanidins; treatment of inflammatory disorders, particularly irritation of the urinary tract due to both bacterial and non-bacterial causes RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-09-18 — — US disclosed
US-20060088610-A1 Anti-inflammatory cranberry flavonol extract preparations RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2006-04-27 — — US disclosed
US-20060088610-A1 Anti-inflammatory cranberry flavonol extract preparations RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2006-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056618-A1 DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES SLC5A2, SLC5A1, SLC2A2 P4HB 2590/4885GAA 1122/4885KDM4E 3890/4885
US-10285973-B2 SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease SLC5A1, SLC5A2, SLC2A1 P4HB 4129/4885GAA 763/4885KDM4E 1229/4885
US-10500186-B2 SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease SLC5A1, SLC5A2, SLC2A1 P4HB 4129/4885GAA 763/4885KDM4E 1229/4885
US-20200297692-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE SLC5A1, SLC5A2, SLC2A1 P4HB 4129/4885GAA 763/4885KDM4E 1229/4885
US-20070292539-A1 Anti-inflammatory cranberry flavonol extract preparations LGALS3, FUT6, GALNT6 P4HB 4447/4885GAA 282/4885KDM4E 714/4885
US-20200054598-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE SLC5A1, SLC5A2, SLC2A1 P4HB 4129/4885GAA 763/4885KDM4E 1229/4885
US-20060088610-A1 Anti-inflammatory cranberry flavonol extract preparations LGALS3, FUT6, GALNT6 P4HB 4447/4885GAA 282/4885KDM4E 714/4885
US-10709684-B2 SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease SLC5A1, SLC5A2, SLC2A1 P4HB 4129/4885GAA 763/4885KDM4E 1229/4885
US-20170304262-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE SLC5A1, SLC5A2, SLC2A1 P4HB 4129/4885GAA 763/4885KDM4E 1229/4885
US-20190142793-A1 SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE SLC5A1, SLC5A2, SLC2A1 P4HB 4086/4885GAA 710/4885KDM4E 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.